Investor Relations

Investor Overview Image

Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. The Company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (PRX003).

NASDAQ: PRTA
$ 35.99
1.55 (4.13%)

Day High: 37.43
Day Low:  35.84
Volume:    440,300
4:00 PM ET
Apr 17, 2015

Delayed ~20 min., by eSignal.

Press Releases

Apr 8, 2015
Apr 6, 2015